Citations

Clear

1031 citation(s) found for "Clark, AS".

A Primer Genetic Toolkit for Exploring Mitochondrial Biology and Disease Using Zebrafish
Sabharwal, Ankit , Campbell, Jarryd M. , Schwab, Tanya L., WareJoncas, Zachary , Wishman, Mark , Ata, Hirotaka , Liu, Wiebin, Hunter, Danielle E., Bergren, Jake D., Urban, Mark D. , Urban, Rhianna , Holmberg, Shannon R. , Kar, Bibekananda , Ekker, Stephen C. , Wishman, Mark D, Ichino, Noriko , Urban, Mark D , Kar, Bibekananda , Cook, Alex, Ding, Yonghe , Ekker, Stephen C , Sabharwal, Ankit , Cook, Alex Richard , Xu, Xiaolei , Clark, Karl J.

Mayo Clinic

Genes | July 24, 2022 | Volume: 13 | Issue: 8 | Pages: 1317

10.3390/genes13081317 | PMID 35893052 Get It

Mitochondria are a dynamic eukaryotic innovation that play diverse roles in biology and disease. The mitochondrial genome is remarkably conserved in all vertebrates, encoding the same 37-gene set and overall genomic structure, ranging from 16,596 base pairs (bp) in the teleost zebrafish (Danio rerio) to 16,569 bp in humans. Mitochondrial disorders are amongst the most prevalent inherited diseases, affecting roughly 1 in every 5000 individuals. Currently, few effective treatments exist for those with mitochondrial ailments, representing a major unmet patient need. Mitochondrial dysfunction is also a common component of a wide variety of other human illnesses, ranging from neurodegenerative disorders such as Huntington’s disease and Parkinson’s disease to autoimmune illnesses such as multiple sclerosis and rheumatoid arthritis. The electron transport chain (ETC) component of mitochondria is critical for mitochondrial biology and defects can lead to many mitochondrial disease symptoms. Here, we present a publicly available collection of genetic mutants created in highly conserved, nuclear-encoded mitochondrial genes in Danio rerio. The zebrafish system represents a potentially powerful new opportunity for the study of mitochondrial biology and disease due to the large number of orthologous genes shared with humans and the many advanced features of this model system, from genetics to imaging. This collection includes 15 mutant lines in 13 different genes created through locus-specific gene editing to induce frameshift or splice acceptor mutations, leading to predicted protein truncation during translation. Additionally, included are 11 lines created by the random insertion of the gene-breaking transposon (GBT) protein trap cassette. All these targeted mutant alleles truncate conserved domains of genes critical to the proper function of the ETC or genes that have been implicated in human mitochondrial disease. This collection is designed to accelerate the use of zebrafish to study many different aspects of mitochondrial function to widen our understanding of their role in biology and human disease.
Author response: Cre/lox regulated conditional rescue and inactivation with zebrafish UFlip alleles generated by CRISPR-Cas9 targeted integration
Kambakam, Sekhar , Almeida, Maira P. , Ming, Zhitao, Wierson, Wesley A. , Schultz‐Rogers, Laura , Liu, Fang , Welker, Jordan M. , Ekker, Stephen C. , Clark, Karl J. , Essner, Jeffrey J. , McGrail, Maura

Mayo Clinic

No container title available | July 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.71478.sa2 Get It

Differential migration mechanics and immune responses of glioblastoma subtypes
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima, McMahon, Mariah, Klank, Rebecca, McFarren, S. Joey, Rosato, Pamela C. , Sarkaria, Jann N., Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , McMahon, Mariah , Shamsan, Ghaidan A , Rosato, Pamela C , Liu, Chao J. , Rathe, Susan K. , Klank, Rebecca L. , Tschida, Barbara R , McFarren, S Joseph. , Masopust, David , Sarkaria, Jann N., Largaespada, David A. , Odde, David J

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.06.26.497270 Get It

Abstract Glioblastoma remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. Here, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared to proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in the mesenchymal tumors, including T cell-mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration, but are immunologically ‘hot’ which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significant Statement This study highlights new mechanical and immunological insights into glioblastoma molecular subtypes using an integrated modeling-genome engineering strategy, which can potentially facilitate glioblastoma subtype-specific therapeutic strategies.
Cre/lox regulated conditional rescue and inactivation with zebrafish UFlip alleles generated by CRISPR-Cas9 targeted integration
Kambakam, Sekhar , Almeida, Maira P. , Ming, Zhitao, Welker, Jordan M. , Wierson, Wesley A. , Schultz‐Rogers, Laura , Ekker, Stephen C. , Clark, Karl J. , Essner, Jeffrey J. , McGrail, Maura , Kambakam, Sekhar , Ekker, Stephen C , Clark, Karl J , Essner, Jeffrey , McGrail, Maura , Liu, Fang

Mayo Clinic

eLife | June 17, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.71478 | PMID 35713402 Get It

The ability to regulate gene activity spatially and temporally is essential to investigate cell-type-specific gene function during development and in postembryonic processes and disease models. The Cre/ lox system has been widely used for performing cell and tissue-specific conditional analysis of gene function in zebrafish. However, simple and efficient methods for isolation of stable, Cre/ lox regulated zebrafish alleles are lacking. Here, we applied our GeneWeld CRISPR-Cas9 targeted integration strategy to generate floxed alleles that provide robust conditional inactivation and rescue. A universal targeting vector, UFlip, with sites for cloning short homology arms flanking a floxed 2A-mRFP gene trap, was integrated into an intron in rbbp4 and rb1. rbbp4 off and rb1 off integration alleles resulted in strong mRFP expression,>99% reduction of endogenous gene expression, and recapitulated known indel loss-of-function phenotypes. Introduction of Cre led to stable inversion of the floxed cassette, loss of mRFP expression, and phenotypic rescue. rbbp4 on and rb1 on integration alleles did not cause phenotypes in combination with a loss-of-function mutation. Addition of Cre led to conditional inactivation by stable inversion of the cassette, gene trapping and mRFP expression, and the expected mutant phenotype. Neural progenitor Cre drivers were used for conditional inactivation and phenotypic rescue to showcase how this approach can be used in specific cell populations. Together these results validate a simplified approach for efficient isolation of Cre/ lox -responsive conditional alleles in zebrafish. Our strategy provides a new toolkit for generating genetic mosaics and represents a significant advance in zebrafish genetics.
Outcomes of a resilient living program for patients with advanced cancer and their caregivers.
Pachman, Deirdre R. , Cutshall, Susanne M. , Mandrekar, Jayawant, Rummans, Teresa A. , Clark, Matthew M. , Chesak, Sherry S. , Lapid, Maria I.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e24087-e24087

10.1200/jco.2022.40.16_suppl.e24087 Get It

e24087 Background: Patients with advanced cancer and their caregivers experience a substantial amount of distress. Limited research suggests that mindfulness-based interventions may improve quality of life and reduce anxiety. The virtually delivered Resilient Living program consisted of online modules, a print journal, and a total of 4 virtual training sessions focused on techniques for managing stress and building resilience (mindful presence, uplifting emotions, reframing experiences through principles of gratitude, compassion, acceptance, meaning, and forgiveness). The current pilot study was performed to assess the feasibility of the virtual Resilient Living Program for patients with advanced cancer and their caregivers, as well as preliminary effects on anxiety and related outcomes. Methods: Eligible patients included those age ≥18 years with a diagnosis of advanced cancer with expected prognosis > 6 months. Feasibility was defined as consent of at least 25% of eligible patients and their caregivers. Adherence was defined as 75% of the enrolled participants completing at least 3 of the 4 Resilient Living sessions. The primary outcome measure was anxiety as measured by the GAD-7; others included stress (PSS), quality of life (LASA), sleep (ISI), resiliency (Resiliency Scale), and fatigue (PROMIS-Fatigue SF). Results: Seventy-two eligible patients were referred to the study, of these 33 patients enrolled (46% enrollment), 15 also had a caregiver enroll. Thirty participants completed at least 3 virtual sessions (63% adherence). Data was collected at baseline, week 5 (after 2 session), week 9 (after 4 sessions), and week 12 (1 month after completion) for patients and caregivers. There were statistically significant improvements in anxiety at weeks 5, 9 and 12 (i.e., p < 0.05). Other results are outlined in the table. Conclusions: Virtual participation in the Resilient Living Program is feasible and acceptable for patients with advanced cancer and their caregivers. Data from this pilot study suggest that the program may positivity impact anxiety, stress, sleep, quality of life and resiliency. A larger randomized prospective clinical trial is warranted to confirm these preliminary findings. Clinical trial information: NCT04480008. [Table: see text]
Seizure forecasting: Bifurcations in the long and winding road
Baud, Maxime O. , Proix, Timothée , Gregg, Nicholas M. , Brinkmann, Benjamin H. , Nurse, Ewan S. , Cook, Mark , Karoly, Philippa J. , Nurse, Ewan , Brinkmann, Benjamin H , Karoly, Phillipa J , Cook, Mark J , Gregg, Nicholas M , Baud, Maxime O

Mayo Clinic

Epilepsia | May 23, 2022 | Volume: 64 | Issue: S4 | Pages: No page available

10.1111/epi.17311 | PMID 35604546 Get It

AbstractTo date, the unpredictability of seizures remains a source of suffering for people with epilepsy, motivating decades of research into methods to forecast seizures. Originally, only few scientists and neurologists ventured into this niche endeavor, which, given the difficulty of the task, soon turned into a long and winding road. Over the past decade, however, our narrow field has seen a major acceleration, with trials of chronic electroencephalographic devices and the subsequent discovery of cyclical patterns in the occurrence of seizures. Now, a burgeoning science of seizure timing is emerging, which in turn informs best forecasting strategies for upcoming clinical trials. Although the finish line might be in view, many challenges remain to make seizure forecasting a reality. This review covers the most recent scientific, technical, and medical developments, discusses methodology in detail, and sets a number of goals for future studies.
Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study
Kukla, Aleksandra , Diwan, Tayyab S. , Smith, Byron H. , Collazo–Clavell, Maria L. , Lorenz, Elizabeth C. , Clark, Matthew M. , Grothe, Karen, Đenić, Aleksandar , Park, Walter D. , Sahi, Sukhdeep , Issa, Naim , Dean, Patrick G. , Kudva, Yogish C. , Diwan, Tayyab , Amer, Hatem , Issa, Naim , Bentall, Andrew , Mundi, Manpreet S , Stegall, Mark D , Smith, Byron , Denic, Aleksandar , Park, Walter , Schinstock, Carrie A. , Amer, Hatem , Bentall, Andrew , Mundi, Manpreet S. , Stegall, Mark D.

Mayo Clinic

Kidney360 | May 23, 2022 | Volume: 3 | Issue: 8 | Pages: 1411-1416

10.34067/kid.0001682022 | PMID 36176651 Get It

Background Obesity is increasingly common in kidney transplant candidates and may limit access to transplantation. Obesity and diabetes are associated with a high risk for post-transplant complications. The best approach to weight loss to facilitate active transplant listing is unknown, but bariatric surgery is rarely considered due to patient- and physician-related apprehension, among other factors. Methods We aimed to determine the magnitude of weight loss, listing, and transplant rates in 28 candidates with a mean BMI of 44.4±4.6 kg/m 2 and diabetes treated conservatively for 1 year post weight-loss consultations (group 1). Additionally, we evaluated 15 patients (group 2) who met the inclusion criteria but received bariatric intervention within the same time frame. All patients completed a multidisciplinary weight management consultation with at least 1 year of follow-up. Results In the conservatively managed group (group 1), the mean weight at the time of initial consultation was 126.5±18.5 kg, and the mean BMI was 44.4±4.6 kg/m 2 . At 1 year post weight-loss consultation, the mean weight decreased by 4.4±8.2 kg to 122.9±17 kg, and the mean BMI was 43±4.8 kg/m 2 , with a total mean body weight decrease of 3% ( P =0.01). Eighteen patients (64%) did not progress to become candidates for active listing/transplantation during the follow-up time of 4±2.9 years, with 15 (54%) subsequently developing renal failure/diabetes-related comorbidities prohibitive for transplantation. In contrast, mean total body weight decreased by 19% at 6 months post bariatric surgery, and the mean BMI was 34.2±4 and 32.5±3.7 kg/m 2 at 6 and 12 months, respectively. Bariatric surgery was strongly associated with subsequent kidney transplantation (HR=8.39 [95% CI 1.71 to 41.19]; P =0.009). Conclusions A conservative weight-loss approach involving multidisciplinary consultation was ineffective in most kidney transplant candidates with diabetes, suggesting that a more proactive approach is needed.
The Association of Race With Adequate Lymph Node Evaluation for Gastric Cancer
Tsao, Miriam , Kahl, Madison S., Deneve, Jeremiah L. , Yakoub, Danny , Shibata, David , Clark, Ian D. , Dickson, Paxton V. , Glazer, Evan S. , Jain, Richa, Clark, Ian

Mayo Clinic

The American Surgeon | May 18, 2022 | Volume: 88 | Issue: 9 | Pages: 2280-2288

10.1177/00031348221101601 | PMID 35570820 Get It

Background National studies have reported racial and socioeconomic disparities in gastric cancer (GC) care. The current study evaluated adequate lymph node (LN) assessment (≥16 LNs) during resection for GC within a healthcare system servicing a socioeconomically disparate, mostly non-White population in the Southeast United States. Methods A retrospective cohort study of patients undergoing resection for GC between 2003-2019 was performed. Factors associated with adequate LN assessment including patient and tumor characteristics were analyzed. Results Among 202 patients, adequate LN assessment was performed in 97 (48%) patients. On univariable analysis, younger age, non-White race, lower Charlson Comorbidity Index (CCI), Medicaid or no insurance, D1+/D2 lymphadenectomy, clinical evidence of regional LN metastases, total gastrectomy, and receipt of neoadjuvant therapy were associated with adequate LN assessment. On multivariable analysis, non-White race (OR 2.79, 95% CI 1.38-5.65), CCI <4 (OR 2.14, 95% CI 1.15-3.96), and D1+/D2 lymphadenectomy (OR 3.63, 95% CI 1.96-6.74) were the only factors independently associated with adequate LN evaluation. Conclusions In the current study, non-White race, independent of socioeconomics, was significantly associated with adequate LN assessment. Future work is necessary to improve standardization and achieve higher rates of adequate LN assessment for all patients during resection for GC.
Necrotizing Enterocolitis in Very Low Birth Weight Neonates: A Natural History Study
Mara, Kristin C. , Carey, William A., Mara, Kristin C , Clark, Reese H.

Mayo Clinic

American Journal of Perinatology | May 12, 2022 | Volume: 41 | Issue: S 01 | Pages: e435-e445

10.1055/a-1851-1692 | PMID 35554890 Get It

Objective We characterize the most recent natural history of necrotizing enterocolitis (NEC), as this is an essential first step in guiding the prevention and treatment of this disease in the present day. Study Design We performed a retrospective cohort study of neonates who were born at 23 to 29 weeks' gestation and birth weight <1,500 g who received care from the Pediatrix Medical Group between 2004 and 2019. We assessed the incidence of medical and surgical NEC and the patterns of initial antibiotic treatment to develop a contemporary cohort for further analysis. Among patients discharged between 2015 and 2019, we characterized the stage-specific risk factors for patients diagnosed with medical or surgical NEC, as well as patterns of disease onset, progression, biomarkers, and outcomes. We used the same approach to characterize patients diagnosed with suspected NEC. Results Among 34,032 patients in the contemporary cohort, 1,150 (3.4%) were diagnosed with medical NEC and 543 (1.6%) were diagnosed with surgical NEC. The temporal pattern of disease onset was different for medical and surgical NEC, with gestational age– and birth weight–specific risk disparities emerging earlier in surgical NEC. Thirty-day mortality was much greater among surgical NEC patients (medical NEC 16.4% vs. surgical NEC 43.0%), as were rates of various in-hospital and long-term outcomes. Suspected NEC was diagnosed in 1,256 (3.7%) patients, among whom risk factors and disease onset, progression, and outcomes closely resembled those of medical NEC. Conclusion Analyzing data from a contemporary cohort enabled us to characterize the current, stage-specific natural history of NEC, including novel insights into suspected NEC. Future studies could leverage this cohort to characterize how specific patient characteristics, care processes, or biomarkers may influence or predict disease outcomes. Key Points